deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT03568656

Study to Evaluate CCS1477 in Advanced Tumours

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

Sponsor: CellCentric Ltd.

Conditions Advanced Solid Tumors Metastatic Breast Cancer Metastatic Castration-Resistant Prostate Cancer Non-small Cell Lung Cancer
Interventions Abiraterone acetate Atezolizumab CCS1477 Darolutamide Enzalutamide Olaparib
Updated 30 times since 2018 Last updated: Aug 5, 2025 Started: Jul 23, 2018 Primary completion: Jul 6, 2025 Completion: Jul 6, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Solid Tumors and Metastatic Breast Cancer and is currently completed. CellCentric Ltd. leads this study, which shows 30 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Jul 2019 · 6 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 25 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  13. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  15. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  17. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  19. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  20. Apr 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  21. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  22. Jan 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  23. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  24. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CellCentric Ltd.
Data source: CellCentric Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Belfast, United Kingdom , Birmingham, United Kingdom , Bordeaux, France , Boston, United States , Cambridge, United Kingdom , Edinburgh, United Kingdom , Glasgow, United Kingdom , Leicester, United Kingdom and 9 more locations